Key result
Diabetic cardiomyopathy is characterized by myocardial hypertrophy and diastolic dysfunction, driven by increased cellular and extracellular matrix stiffness, impaired NO pathway, and inflammation.
Why the study?
Cardiomyopathy is an important cause of heart failure in diabetic patients, but its pathophysiology leading to myocardial hypertrophy and diastolic dysfunction has not been completely understood.
Design
Review article
Authors
Loading...
Supports stiffness- and inflammation-focused model of diabetic cardiomyopathy; leaves open prospective validation before clinical adoption.
This review outlines the complex pathophysiological mechanisms underlying diastolic dysfunction in diabetic cardiomyopathy, highlighting potential therapeutic targets such as the NO pathway and SGLT-2.
Starčević et al. (2019) conducted a review in Diabetic cardiomyopathy. Diabetic cardiomyopathy is characterized by myocardial hypertrophy and diastolic dysfunction, driven by increased cellular and extracellular matrix stiffness, impaired NO pathway, and inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: